Prostate Cancer
Conditions
Brief summary
This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
Interventions
HS-20093 for injection.
DRUGSHR3680 Tablet
SHR3680 tablet.
DRUGAbiraterone Tablet
Abiraterone tablet.
DRUGSHR2554 Tablet
SHR2554 tablet.
Enzalutamide tablet.
DRUGDarotamine Capsule
Darotamine capsule.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntarily participate in this clinical study, understand the research procedures, and are able to provide written informed consent. 2. Aged 18 to 80 years (inclusive), male. 3. ECOG performance status of 0 or 1. 4. Expected survival time ≥12 weeks. 5. Histologically or cytologically confirmed prostate adenocarcinoma, with no features of neuroendocrine carcinoma or small cell carcinoma. 6. Able to provide sufficient tumor tissue samples for retrospective genetic testing. 7. Ongoing Androgen Deprivation Therapy (ADT) throughout the study period, i.e., continuous treatment with a GnRH agonist or antagonist (chemical castration) or prior bilateral orchiectomy (surgical castration). 8. PSA level ≥1 ng/ml at screening. 9. Adequate organ function levels at baseline assessment. 10. Male participants with female partners of childbearing potential must agree to refrain from sperm donation and use effective contraception from the time of signing the informed consent form until 4.5 months after the last dose of HS-20093 or 3 months after the last dose of other study treatments, whichever is later.
Exclusion criteria
1. Known hypersensitivity or intolerance to the investigational drug(s) or their excipients. 2. Adverse events from prior anti-tumor therapy have not recovered to Grade ≤1 as per CTCAE v5.0. 3. Administration of estrogen, progesterone, or 5-alpha reductase inhibitors within 28 days prior to enrollment. 4. Administration of herbal medicines known to have anti-prostate cancer or PSA-lowering effects within 14 days prior to enrollment. 5. Major surgery within 28 days prior to enrollment; palliative radiotherapy within 14 days prior to enrollment; or traumatic minor surgery within 7 days prior to enrollment. 6. Pathological fractures in critical locations, spinal cord compression, etc., within the recent 6 months. 7. Non-healing wounds, untreated fractures, or severe bone damage due to metastatic disease. 8. Poorly controlled tumor-related pain. 9. Dysphagia or other conditions significantly affecting drug absorption. 10. Known central nervous system metastases or primary brain tumors. 11. Significant pericardial, pleural, or peritoneal effusion requiring intervention. 12. Severe cardiovascular or cerebrovascular diseases. 13. Moderate to severe pulmonary disease significantly affecting respiratory function. 14. Poorly controlled diabetes. 15. Serious active infections within 14 days prior to enrollment. 16. Active Hepatitis B, Hepatitis C, HIV, or immunodeficiency diseases. 17. History of other malignancies within 5 years prior to enrollment. 18. Any other condition deemed by the investigator to potentially affect the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cohort 1: 6-month undetectable Prostate Specific Antigen (PSA) rate. | 6 months. |
| Cohort 2: Prostate Specific Antigen (PSA) response rate. | About 2 years. |
| Cohort 2: Adverse events (AEs). | About 2 years. |
| Cohort 2: Dose-limiting toxicity (DLT). | About 28 days. |
Secondary
| Measure | Time frame |
|---|---|
| Radiographic Progression-Free Survival (rPFS). | About 2 years. |
| Time to Prostate Specific Antigen (PSA) progression. | About 2 years. |
| Time to Next Symptomatic Skeletal Event (SSE). | About 2 years. |
| Time to Next Antineoplastic Therapy (TTNT). | About 2 years. |
| Objective response rate (ORR). | About 2 years. |
| Cohort 1: Adverse events (AEs). | About 2 years. |
| Disease control rate (DCR). | About 2 years. |
| Duration of response (DoR). | About 2 years. |
| Overall Survival (OS). | About 2 years. |
Countries
China
Contacts
CONTACTWenliang Wang
CONTACTQi Zhang
Outcome results
None listed